e-learning
resources
Munich 2006
Monday 04.09.2006
Established and experimental therapies for allergic asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cost effectiveness of omalizumab in Swedish asthma patients
S. Dewilde, P. Dale, F. Turk (Bussels, Belgium; London, United Kingdom; Basel, Switzerland)
Source:
Annual Congress 2006 - Established and experimental therapies for allergic asthma
Session:
Established and experimental therapies for allergic asthma
Session type:
Thematic Poster Session
Number:
2569
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Dewilde, P. Dale, F. Turk (Bussels, Belgium; London, United Kingdom; Basel, Switzerland). Cost effectiveness of omalizumab in Swedish asthma patients. Eur Respir J 2006; 28: Suppl. 50, 2569
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study.
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
The effectiveness of omalizumab in steroid-dependent asthma patients
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Real-life effectiveness of omalizumab in difficult-to-treat
versus
severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019
Safety and efficacy of omalizumab in children with allergic asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
Cost of asthma in patients treated with national asthma guideline in Turkey
Source: Eur Respir J 2003; 22: Suppl. 45, 481s
Year: 2003
Cost of asthma rescue/acute and allergy medications among asthmatic patients on controller therapy
Source: Eur Respir J 2004; 24: Suppl. 48, 344s
Year: 2004
Cost effectiveness of bronchial thermoplasty for treatment of severe asthma patients in spain
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Economic costs of severe asthma in omalizumab-treated patients. FENOMA Study
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017
The eXpeRience registry: Monitoring the ‘real-world‘ effectiveness of omalizumab in allergic asthma
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Cost implications for the introduction of omalizumab in to the management of severe chronic asthma in children
Source: Eur Respir J 2006; 28: Suppl. 50, 481s
Year: 2006
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Safety of omalizumab therapy in children with allergic asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Physician assessment of asthma control in patients receiving omalizumab in a real-world setting
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting
Source: International Congress 2017 – Asthma management
Year: 2017
BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept